

Research Article

Effects of PON Polymorphisms and Haplotypes on Molecular Phenotype in Mexican-American Mothers and Children

Karen Huen,¹ Lisa Barcellos,¹ Kenneth Beckman,² Sherri Rose,¹
Brenda Eskenazi,¹ and Nina Holland^{1*}

¹Center for Children's Environmental Health, School of Public Health, University of California, Berkeley, California

²Children's Hospital Oakland Research Institute, Functional Genomics Core Oakland, California

Paraoxonase 1 (PON1) prevents oxidation of low-density lipoproteins and inactivates toxic oxon derivatives of organophosphate pesticides (OPs). More than 250 SNPs have been previously identified in the *PON1* gene, yet studies of *PON1* genetic variation focus primarily on a few promoter SNPs (–108, –162) and coding SNPs (192, 55). We sequenced the *PON1* gene in 30 subjects from a Mexican-American birth cohort and identified 94 polymorphisms with minor allele frequencies >5%, including several novel variants (six SNPs, one insertion, and two deletions). Variants of the *PON1* gene and three SNPs from *PON2* and *PON3* were genotyped in 700 children and mothers from the same cohort. PON1 phenotype was established using two substrate-specific assays: arylesterase (AREase) and paraoxonase (POase). Twelve *PON1* and two *PON2* polymorphisms were significantly associated with AREase activity, and 37 polymor-

phisms with POase activity; however, only nine were not in strong linkage disequilibrium (LD) with either *PON1*_{–108} or *PON1*₁₉₂ ($r^2 > 0.20$), SNPs with known effects on PON1 quantity and substrate-specific activity. Single tagSNPs *PON1*₅₅ and *PON1*₁₉₂ accounted for similar ranges of AREase variation compared to haplotypes comprised of multiple SNPs within their haplotype blocks. However, *PON1*₅₅ explained 11–16% of POase activity, while six SNPs in the same haplotype block explained threefold more variance (36–56%). Although LD structure in the *PON* cluster seems similar between Mexicans and Caucasians, allele frequencies for many polymorphisms differed strikingly. Functional effects of *PON* genetic variation related to susceptibility to OPs and oxidative stress also differed by age and should be considered in protecting vulnerable subpopulations. Environ. Mol. Mutagen. 52:105–116, 2011. © 2010 Wiley-Liss, Inc.

Key words: functional genomics; oxidative stress; pesticides; indels; haplotype blocks; children

INTRODUCTION

Paraoxonase 1 (PON1) is considered a protective metabolic enzyme because it can detoxify the oxon derivatives of some organophosphate pesticides (OPs), which are known to be neurotoxic [Li et al., 2003; Costa et al., 2005a]. More recently, PON1 research has intensified as multiple studies have established an antioxidant role of not only *PON1* (MIM 168820), but additional members of the *PON* gene family cluster, *PON2* (MIM 602447) and *PON3* (MIM 602720) [Li et al., 2003; Aviram and Rosenblat, 2004; Horke et al., 2007]. We previously demonstrated wide inter-individual variability of PON1 phenotypes in mothers and children [Furlong et al., 2006]. This variability may confer differential susceptibilities to OPs exposures and oxidative stress. Although the physiological

mechanisms linking PON1 and disease have not been clearly established, several epidemiological studies have reported associations between PON1 genotypes and enzyme activities and many diseases including cardiovascular disease

Grant sponsor: U.S. Environmental Protection Agency; Grant Numbers: R826886, R82670901; Grant sponsor: National Institute of Environmental Health Science; Grant Numbers: R01ES012503-03, PO1 ES009605.

*Correspondence to: Nina Holland, 50 University Hall, School of Public Health, UC Berkeley, CA 94720-7360.

E-mail: ninah@berkeley.edu

Received 16 December 2009; provisionally accepted 2 February 2010; and in final form 4 February 2010

DOI 10.1002/em.20567

Published online 26 March 2010 in Wiley Online Library (wileyonlinelibrary.com).

[Bhattacharyya et al., 2008], Parkinson's disease [Zintzaras and Hadjigeorgiou, 2004], Alzheimer's disease [Erlich et al., 2006], and diabetes [Li et al., 2005].

Factors mediating PON1 expression and enzyme activity may play a key role in determining susceptibility to OP exposure and oxidative stress. Genetics appear to have the strongest influence on PON1 phenotype [Deakin and James, 2004; Costa et al., 2005b]. Three members of the *PON* gene cluster, *PON1*, *PON2*, and *PON3* are adjacent to each other over a 120-kb region on the long arm of chromosome 7q21.3-22 and share approximately 65% homology at the amino acid level [Primo-Parmo et al., 1996]. While all three PON enzymes exhibit antioxidant properties [Aviram and Rosenblat, 2004], only PON1 is capable of metabolizing toxic oxon derivatives of OPs [Draganov et al., 2005]. Studies have reported strong LD between polymorphisms in the *PON2* and *PON3* genes [Erlich et al., 2006; Landers et al., 2008] and some also suggest presence of LD between certain *PON1* and *PON3* SNPs [Landers et al., 2008; Sanghera et al., 2008]. Few studies have examined the effect of *PON2* and *PON3* SNPs on PON1 phenotype; however, Sanghera et al. [2008] have reported associations between several *PON3* tagSNPs on PON1 activity.

Although more than 250 polymorphisms in the *PON1* gene exist, most studies focus primarily on just a few known functional SNPs (*PON1*₋₁₆₂, *PON1*₋₁₀₈, *PON1*₅₅, and *PON1*₁₉₂). Promoter SNPs, *PON1*₋₁₆₂, and *PON1*₋₁₀₈, are strongly associated with PON1 levels although *PON1*₋₁₀₈ SNP has the largest impact [Brophy et al., 2001]. PON1 levels for the *PON1*_{-108C} allele are on average twofold higher than for the *PON1*_{-108T} allele [Deakin et al., 2003]; in vivo studies suggest that this SNP may disrupt an Sp1 recognition sequence thereby affecting transcription [Deakin et al., 2003]. *PON1*₅₅, a coding SNP, is also associated with PON1 levels; however, much of this effect has been attributed to its strong linkage disequilibrium with promoter SNPs [Brophy et al., 2001]. The nonsynonymous coding SNP, *PON1*₁₉₂, results in an amino acid substitution from glutamine (Q) to arginine (R), dramatically affecting substrate-specific catalytic efficiency. In vitro and in vivo studies have demonstrated that the *PON1*_{192R} alloform can hydrolyze OP oxons chlorpyrifos-oxon and paraoxon more efficiently than the *PON1*_{192Q} alloform, therefore conferring a greater degree of protection from OP exposures [Costa et al., 2003]. Furthermore, structural studies using directed evolution suggest that amino acid residue Lys192 is likely part of the PON1 active site wall [Harel et al., 2004].

Several studies have demonstrated that *PON1*₁₉₂ accounts for most of the variability of POase activity. For example, it explains 59% of POase activity among Caucasian and African-American adults [Bhattacharyya et al., 2008] and 48% of the variability in a Mexican-American population [Rainwater et al., 2009]. We previously showed

that five known SNPs explain less POase variability in Mexican-American newborns (49%) in comparison to their mothers (63% and 78% at the time of delivery and 7 years later, respectively) [Huen et al., in press]. In contrast, the same five SNPs explain only 27% of AREase variability in newborns and even less in mothers at the time of delivery (12%); Chen et al. [2003] reported a similar trend in Caucasians, African-Americans, and Caribbean Hispanics. These data suggest that the impact of genetic polymorphisms on PON1 phenotype may differ by age. Furthermore, additional genetic variants and other factors may also influence AREase activity and therefore PON1 expression.

Studies of *PON1* genotypes and phenotypes in different ethnic populations have revealed significant variation in both allele frequencies and PON1 activities. For example, the frequency of the *PON1*_{192Q} allele, which is associated with slower catalytic efficiency towards some OPs (e.g., chlorpyrifos-oxon), has a high frequency in Caucasians (0.73), but a significantly lower frequency in Mexicans (0.48) and African-Americans (0.37) [Chen et al., 2003; Rojas-Garcia et al., 2005; Holland et al., 2006]. Similarly, the *PON1*_{-108C} allele associated with increased PON1 expression has a high frequency in African-Americans (0.85) and much lower frequency in Caucasians (0.38) [Chen et al., 2003; Rojas-Garcia et al., 2005; Holland et al., 2006]. On the haplotype level, Koda et al. [2004] demonstrated that frequencies in the *PON1* gene differed widely between African, European, and Japanese populations. Furthermore, certain haplotypes were unique to specific populations. Chen et al. [2005] also demonstrated that the genetic contribution of five known SNPs (at positions -909, -162, -108, 55, and 192) to AREase activity differs between populations. In Caucasian newborns, they accounted for 70% of activity while in African-Americans and Caribbean Hispanics, they only explained 15 and 24%, respectively.

The *PON1* gene has been resequenced in several populations including Yoruba of Ibadan, Nigeria, Han Chinese, Japanese, Utah residents with Northern and Western European ancestry (CEPH), and African-Americans (based on data from HapMap: <http://hapmap.ncbi.nlm.nih.gov>; and Seattle SNPs databases: <http://pga.gs.washington.edu>). To our knowledge, no resequencing data and limited genotyping data is available in Mexican and other Hispanic populations. The current data demonstrating significant differences between populations suggest that there may be genetic variants unique to or more frequent in Mexican populations in comparison to other ethnic groups. Furthermore, the genetic contribution of certain polymorphisms to enzyme activity and expression may also differ between age groups. To further characterize genetic variation of *PON1* and *PON* family cluster genes *PON2* and *PON3* in a Mexican-American birth cohort from California, we resequenced all three *PON* genes in 30 mothers and children, and then determined the functional signifi-

cance of identified polymorphisms and haplotypes in more than 200 mothers and 200 newborns. Since many studies focus primarily on coding SNPs *PON1*₁₉₂ and *PON1*₅₅, we also examined how well these single SNPs characterize the variation of PON1 enzyme levels and substrate-specific activities in comparison to multiple SNPs from the same haplotype block.

MATERIALS AND METHODS

Study Subjects

The Center for Health Assessment in Mothers and Children of Salinas (CHAMACOS) is a longitudinal birth cohort of primarily Mexican-American families from the agricultural region Salinas Valley in Northern California [Eskenazi et al., 2003]. Enrollment of 601 pregnant women took place from 1999 to 2000. Five hundred and thirty-one of the mothers were followed through the birth of a live infant. Mothers in the CHAMACOS cohort were primarily young (mean \pm SD: 25.6 \pm 5.3 years), Mexican-born, Spanish-speaking women. Many of them worked in agriculture (44%) and/or lived with farm workers at the time of enrollment (84%). Ethnicity of children and mothers was based on mothers' self-report. For this analysis, we included only women and children who were of Hispanic origin, the majority of whom were Mexican (>90%). More than half of the women in CHAMACOS came from three states in Mexico: Michoacán (23%), Guanajuato (21%), and Jalisco (11%). Although we did not analyze genotypes in fathers, questionnaire data revealed that among women of Hispanic origin in this study 96% of fathers were also of Hispanic origin (reported by mothers). Therefore, women and children included in this analysis were from a relatively homogeneous population. Study protocols were approved by the University of California, Berkeley human-subjects review committee. Written informed consent was obtained from all mothers.

Blood Collection and Processing

Blood specimens were collected from mothers at the hospital shortly before or after the time of delivery. Umbilical cord blood samples were collected by delivery room staff once the baby was safely delivered. Heparinized whole blood was collected in BD vacutainers[®] (Becton, Dickinson and Company, Franklin Lakes, NJ), centrifuged, divided into plasma, buffy coats and red blood cells, and stored at -80°C . Vacutainers without anticoagulant were used to collect serum and clot. DNA was isolated from blood clots as described previously [Holland et al., 2006].

Resequencing of the *PON1* Gene

Genomic DNA from subjects with a range of high and low PON1 activities was selected for resequencing. All exons (2,393 bp), the majority of introns (21,736 bp), and 5,000 bp portions of the flanking regions up (including the 5' regulatory region) and downstream (including the 3' UTR region) of the *PON1* gene were sequenced in 14 mothers and 16 unrelated children from the CHAMACOS cohort. All exons in *PON2* (1,653 bp) and *PON3* (1,074 bp) were also resequenced in these subjects. Resequencing was conducted by Polymorphic DNA Technologies (Alameda, CA). DNA was sequenced both in the forward and reverse directions.

Linkage Disequilibrium Plot of Resequencing Data and TagSNP Selection

Haploview 4.1 [Barrett et al., 2005] was used to create the LD plot containing PON1 SNPs (including 1,000 bp up and downstream of the gene) with minor allele frequency (MAF) > 0.10 identified by resequencing of genomic DNA from 30 subjects. SNPs whose genotype distributions differed significantly from expected Hardy-Weinberg equilibrium (χ^2 *P*-value < 0.05) were not plotted. The tagger function in Haploview was used to choose a minimal set of tagSNPs ($n = 40$) that captured all alleles with a minimal r^2 of 0.80. We chose to force inclusion of the four known functional SNPs: *PON1*₋₁₆₂, *PON1*₋₁₀₈, *PON1*₅₅, and *PON1*₁₉₂.

quencing of genomic DNA from 30 subjects. SNPs whose genotype distributions differed significantly from expected Hardy-Weinberg equilibrium (χ^2 *P*-value < 0.05) were not plotted. The tagger function in Haploview was used to choose a minimal set of tagSNPs ($n = 40$) that captured all alleles with a minimal r^2 of 0.80. We chose to force inclusion of the four known functional SNPs: *PON1*₋₁₆₂, *PON1*₋₁₀₈, *PON1*₅₅, and *PON1*₁₉₂.

Genotyping of PON Genetic Variants

Following resequencing of the entire *PON1* gene and the exons of the *PON2* and *PON3* genes in 60 chromosomes, we genotyped a subset of SNPs, as well as insertions and deletions (indels) in a larger set of 361 mothers and 339 children. We genotyped a panel of polymorphisms including 33 tagSNPs chosen by tagger including five *PON1* SNPs genotyped for previous analyses [Holland et al., 2006], two *PON2* coding SNPs, two *PON3* SNPs, and four novel SNPs with MAF > 0.05. Since little data on *PON1* indels exist, we also genotyped seven indels with MAF > 0.05. As our tagger results were based on limited data from only 30 subjects, we chose to include additional SNPs from within regions of high LD to ensure adequate coverage. We excluded three SNPs with MAF < 0.05 (rs1997230, rs1003504, and I1_Ins_A<C) and all further analyses were based on the remaining 44 SNPs with MAF > 0.05.

Genotyping of the *PON1*₋₁₆₂, *PON1*₅₅, and *PON1*₁₉₂ polymorphisms was performed using the Taqman real-time PCR method. Primers for the nucleotide sequence flanking the SNP, and probes specific for the SNP were custom-designed by Applied Biosystems (Foster City, CA). *PON1*₋₁₀₈ was genotyped using a fluorogenic allele-specific genotyping assay (Amplifluor). The *PON1*₋₁₀₈ genotype required a two-part nested PCR strategy where the region surrounding the SNP was preamplified using nonallelic flanking primers before this amplicon was diluted and used as the template for the Amplifluor assay. All remaining SNPs and indels were genotyped using the multiplex platform iPLEX (Sequenom, San Diego, CA). Random repeats and blanks were used as a quality assurance and control measure. More than 5% of samples were randomly repeated with a concordance rate of >99.9%. Genotype completion rate was 99.3%.

PON1 Enzyme Activity Assays

Of the 361 mothers and 339 children for whom we genotyped the panel of 44 *PON* polymorphisms, 250 mothers and 203 newborns had plasma specimens available for assessment of PON1 enzymatic activity. The arylesterase (AREase) assay, which measures the rate of hydrolysis of phenyl acetate, is considered a marker of PON1 quantity. Several studies have reported a high correlation between Western Blot and ELISA methods using PON1 antibodies and AREase activity ($r > 0.85$) [Kujiraoka et al., 2000; Connelly et al., 2008]. The paraoxonase (POase) assay, which reflects both enzyme quantity and catalytic efficiency, measures the rate of hydrolysis of paraoxon (PO), the oxon derivative of the OP pesticide parathion.

PON1 substrate-specific assays were performed as described previously [Huen et al., 2009]. Briefly, levels of AREase and POase activity were determined using a Molecular Devices SpectraMax[®] PLUS Microplate Spectrophotometer. After the addition of 20 μL (1:80 dilution) of plasma to 200 μL of a 3.26 mM phenyl acetate solution (9 mM Tris-HCL, pH 8.0, 0.9 mM CaCl_2), the rate of formation of phenol was monitored every 15 sec for 2 min (270 nm, ambient temperature) for measurement of AREase activity. For POase activity determination, the rate of formation of *p*-nitrophenol was measured after the addition of 20 μL (1:10 dilution) of plasma to 200 μL of 1.2 mM paraoxon (2 M NaCl, 0.1 M Tris-HCL, pH 8.5, 2.0 mM CaCl_2) every 15 sec for 2 min (405 nm, 37°C).




Fig. 1. Distribution of *PON1* genetic variants. *PON1*, which has been mapped to the long arm of chromosome 7q21.3, was resequenced in 30 Mexican-American subjects (14 mothers and 16 unrelated children). The distribution of SNPs identified throughout the *PON1* gene (introns, exons, and 5' and 3' UTR regions) is shown. Numbers in the top row represent the

number of SNPs with minor allele frequencies (MAFs) greater than 10% within each labeled region. Numbers in the middle row represent the number of SNPs with MAFs from 5 to 10% and those in the bottom row are for SNPs with MAF < 5%. Overall, 12 indels and 126 SNPs were identified. The majority of the polymorphisms ($n = 86$) had MAFs > 10%.

Statistical Analysis

Assuming a binomial distribution for the likelihood of finding polymorphic sites, our a priori power calculations revealed that resequencing of 60 chromosomes (from 30 subjects) would yield with 95% confidence all polymorphisms occurring with 5% frequency or higher. We also calculated the power to detect associations between SNPs and *PON1* activity using a codominant model. We used a conservative Bonferroni-adjusted significance value of 0.0009 (adjusting for 54 SNPs) and determined that in a population of 250 mothers, there was 80% power to detect of difference of 223 U/L in *POase* activity for SNPs with a MAF of 0.5. In SNPs with a MAF of 0.2, there was 80% power to detect of difference of 302 U/L in *POase* activity.

Although additional factors such as nutrition and alcohol and tobacco consumption [Deakin and James, 2004; Costa et al., 2005b] also influence *PON1* activity, genetics have been shown to play a much more significant role. Using univariate regression models, we determined whether variables such as OP exposure (urinary dialkylphosphate metabolites), alcohol, and tobacco consumption, and some sociodemographic factors were also associated with *PON1* activity in our CHAMACOS subjects. Of the potential confounders tested, only the number of years that the mother lived in the United States, which was previously shown to be correlated with differences in nutrition in the CHAMACOS cohort [Harley et al., 2005], was negatively associated with *AREase* and *POase* activity in newborns ($P = 0.04$ and $P = 0.02$, respectively). However, in this article, we focused on the effects of genotypes and age on *PON1* activity, inclusion of the length of time lived in the United States in statistical models did not significantly change the relationship between the main variables of interest (genetic polymorphisms) and *PON1* enzymatic activities (data not shown).

Gendist software was used to calculate the Nei's genetic distance based on allele frequencies in our Mexican CHAMACOS subjects from Salinas Valley, Hap Map Mexicans from Los Angeles and Seattle SNPs Caucasians (<http://www.psc.edu/general/software/packages/phylip/manual/gendist.html>). We used a chi squared test to compare allele frequencies between mothers and children and also to compare allele frequencies from sequencing to those calculated from genotyping data.

To determine the functional significance of the 44 polymorphisms in our genotyping panel, we used PLINK 1.06 [Purcell et al., 2007] to perform single-marker association tests. The false discovery rate (FDR) method of Benjamini and Hochberg [1995] was used to adjust for multiple testing. To determine whether SNPs significantly associated with *AREase* or *POase* activity further improved the variance explained by the five well-characterized SNPs (at positions -162, -108, 55, and 192), we calculated the difference between coefficients of determination (R^2) for the full model including the SNP in question and the five known SNPs in comparison to a restricted models containing just the five known SNPs in STATA 10.0 (College Station, TX). A post-estimation Wald test was then performed to examine whether the fit of the full model was significantly better than the restricted model containing only the four well-known SNPs. PLINK was also used to compare the propor-

tion of variance explained by functional SNPs versus multiple SNPs from the haplotype block within which they reside. The coefficient of determination (R^2) of the regression model containing the single functional SNP (*PON1*₅₅ or *PON1*₁₉₂) was calculated for both *AREase* and *POase* activity in mothers and children. Similarly, regression models (conditional haplotype-based testing) using inferred haplotypes comprised of multiple SNPs from either haplotype block 1 or 2 were performed for both *AREase* and *POase* activity.

RESULTS

Identification of Genetic Variants in the *PON* Gene Cluster

In the *PON1* gene, we identified 126 SNPs, four insertions, and eight deletions in CHAMACOS mothers and children. The distribution of polymorphisms (including SNPs, insertions, and deletions) throughout the gene and approximate frequencies are shown in Figure 1. We did not observe any significant differences in allele frequencies of these genetic variants in mothers compared to children ($P \gg 0.05$, χ^2 test). Only 15 genetic variants were located in exons, while the majority of them (70%) were found in intronic regions. Of the *PON1* polymorphisms identified in the Mexican-American CHAMACOS subjects, 26 SNPs, two insertions, and two deletions have not been reported in the current build (130) of the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>). In *PON2*, we observed two known nonsynonymous SNPs in exons 5 and 9 (A148G, rs12026; and S311C, rs7493) with MAF = 23% and also two novel polymorphisms in exon 9: a rare (MAF = 2%) SNP and a three-base pair insertion (MAF = 7%). In *PON3* exons, we found only two SNPs. Both were common (MAF = 23 and 40% for rs13226149 and rs1053275, respectively) and had been previously described in other populations.

SNPs with a minor allele frequency greater than 20% in Mexican-American subjects from Northern California (Salinas Valley) are presented in Table I. Allele frequencies calculated from sequencing DNA from 30 subjects were not significantly different from those determined by subsequent genotyping (in parentheses in Table I) of DNA from more than 700 subjects after adjusting for multiple

TABLE I. PON1 SNPs in Mexican-American Mothers and Children (MAF \geq 20%)

RS	Position (chromosome)	Genomic context or predicted function	Major allele/minor allele	HWE	MAF in Salinas Mexicans ^a	Frequency in HapMap Mexicans (Los Angeles) ^b	Frequency in Seattle SNPs Caucasians ^b
rs854572	94792632	Promoter (-909)	G/C	1.00	48 (46)	56	32
rs854571	94792555	Promoter	C/T	0.94	41	37	22
rs705381	94791885	Promoter (-162)	C/T	0.84	28 (20)	16	18
rs705379	94791831	Promoter (-108)	A/G	0.68	45 (45)		41
rs854570	94790628	Intron	A/C	0.59	36 (42)	43	24
rs2237583	94788113	Intron	C/T	0.42	30 (36)	40	36
rs854569	94787991	Intron	G/T	0.86	38 (37)	36	17
rs2299262	94787864	Intron	C/T	1.00	37	52	43
rs854568	94787737	Intron	A/G	1.00	40	33	17
rs2299261	94787599	Intron	A/G	1.00	25	13	37
rs2049649	94787265	Intron	A/G	0.02	47 (40)	62	28
rs3917490	94786777	Intron	T/C	0.12	35	22	48
rs854565	94786280	Intron	G/A	0.82	25	22	20
rs854564	94786118	Intron	T/G	0.82	25		20
rs3917493	94785964	Intron	T/C	0.61	20		2
rs854563	94785945	Intron	G/A	0.02	27 (17)		50
rs854562	94785905	Intron	C/T	0.17	27		41
rs2074351	94785735	Intron	G/A	0.64	27 (32)	38	28
rs854561	94784953	Intron	C/T	0.13	27 (18)	17	50
rs28699500	94784842	Intron	A/G	0.72	27		
rs705378	94784507	Intron	G/T	0.05	28	17	48
rs3917498	94784191	Intron	G/T	0.42	47	61	30
rs854560	94784020	Coding L55M	A/T	0.05	28 (18)		50
rs854559	94783808	Intron	G/A	0.05	28		50
rs2301711	94783595	Intron	T/C	0.61	20	20	2
rs3917503	94783389	Intron	C/T	0.42	47 (48)		30
rs854558	94783310	Intron	C/T	0.82	25 (31)		20
rs854557	94783151	Intron	T/G	0.05	28		50
rs854556	94782859	Intron	C/T	0.05	28		50
rs2299259	94781333	Intron	G/A	0.60	28		28
rs3917515	94780019	Intron	G/A	0.61	20		2
rs3917518	94779717	Intron	C/A	0.20	22 (18)		2
rs3917521	94779351	Intron	G/A	0.64	27 (27)	28	13
rs1157745	94778974	Intron	G/T	0.08	47		17
rs3917527	94778194	Intron	T/C	0.61	20	20	3
rs3917529	94778171	Intron	A/G	0.12	47		15
rs3917532	94778055	Intron	A/T	0.12	47		9
rs3917533	94777766	Intron	G/A	0.64	27		13
rs3917534	94777733	Intron	T/C	0.12	47		17
rs2057681	94776193	Intron	A/G	0.12	47 (49)	53	18
rs2158155	94776112	Intron	G/A	0.61	20		2
rs3917538	94775829	Intron	G/A	0.00	38	28	16
rs3917541	94775560	Intron	G/A	0.61	20		2
rs662	94775382	Coding Q192R	T/C	0.12	47 (49)	52	17
rs3917542	94774628	Intron	C/T	0.64	27 (27)	28	13
rs2269829	94774065	Intron	A/G	0.09	43	48	15
rs3917548	94773841	Intron	A/G	0.61	20	20	2
rs2237582	94772136	Intron	A/G	0.12	47		17
rs3917556	94771125	Intron	T/C	0.51	20		2
rs3917558	94770840	Intron	T/C	0.20	22		4
rs7792044	94769207	Intron	T/C	0.84	22		
rs854555	94768327	Intron	C/A	1.00	45	51	16
rs3917572	94767126	Intron	A/G	0.80	22		2
rs854553	94766682	Intron	G/A	0.66	39		13
rs854552	94765860	utr-3	T/C	0.12	35 (36)	37	13
rs3735590	94765431	utr-3	G/A	0.00	32	22	2
rs854549	94764521	utr-3	C/A	0.46	25 (17)		39
rs10241881	94764042	utr-3	G/A	0.80	22		

^aAllele frequencies from sequencing in 60 chromosomes. Additionally, allele frequencies from genotyping in 339 children and 361 mothers are in parentheses.

^bFrequencies are for the minor allele in Salinas Mexicans. Frequencies for HapMap Mexicans were from genotyping of 90 individuals of Mexican Ancestry in Los Angeles, CA. Frequencies for Seattle SNPs Caucasians were from genotyping of 60 CEPH individuals.

TABLE II. Insertions and Deletions Identified in Mexican-American Mothers and Children

RS	Position (chromosome)	Genomic context or predicted function	Major allele/minor allele	Frequency in Salinas Mexicans (sequencing data) ^a	MAF in Salinas Mexicans (genotyping data) ^b	MAF in Seattle SNPs Caucasians ^c
Insertions						
I1_Ins_A ^d	94787415	Intron	—/A	3	0	
I1_Ins_TTT ^d	94786494	Intron	—/TTT	13		
rs34459620	94786494	Intron	—/TTTT	20		
rs3917539	94775633	Intron	—/AA	34	47	19
Deletions						
FUTR_De1_ATG ^d	94794927	utr-5	ATG/—	7	22	
rs3917506	94782120	Intron	A/—	10	30	28
rs3917525	94778416	Intron	G/—	10	28	13
rs3917549	94773136	Intron	A/—	23		13
rs3917562	94770601	Intron	TGCT/—	10	33	10
rs59551306	94769370	Intron	AAAAAAAAC/—	11		
I8_De1_AC ^d	94766492	Intron	AC/—	7		
rs3832528	94765277	utr-3	CTTT/—	30		

^aFrequency of indels from resequencing of 60 chromosomes. For identification of individuals with double deletions and does not differentiate between those with one or two copies of an insertion. Thus frequency here represents the numbers of individuals with double deletion genotypes (for deletions) or at least one insertion (for insertions).

^bMinor allele frequency (MAF) is shown for genotyping data in Salinas Mexicans.

^cDNA from 23 CEPH (Cohort of Utah residents with Western and European ancestry) were sequenced.

^dUnknown insertions and deletions are named first for location (I, intron; E, exon; FUTR-5' UTR), type of polymorphism (Ins, insertion; Del, deletion), and then the base pair changes.

comparisons (chi-squared test). Using aggregate allele frequency data, we found that the calculated Nei's genetic distance (D) between Salinas Mexicans and HapMap Mexicans from Los Angeles was shorter (0.1) than the distance between Salinas Mexicans and Seattle SNPs Caucasians (0.3). The allele frequencies for most (but not all) of the SNPs present in subjects were similar in range to those reported in Mexicans from Los Angeles, California, in the Hap Map 3 genotyping database [The International HapMap Consortium, 2003]. For instance, for the coding SNP *PONI*₁₉₂, the frequency of the C allele (which results in the amino acid arginine, R) was 47 and 52% in Salinas Mexicans and Los Angeles Mexicans, respectively. In contrast, for many SNPs, the allele frequencies were quite different in Salinas Mexicans compared to Caucasians in the Seattle SNPs database. For example, 13 SNPs with less than 10% MAF in Caucasians (Seattle SNPs) had frequencies $\geq 20\%$ in Salinas Mexicans. There were also a few SNPs whose frequencies were more comparable to those reported in Caucasians than Hap Map Mexicans (i.e., rs2299261 and rs2074351).

Indels identified in our cohort are summarized in Table II. Frequencies ranged from 3 to 34% for insertions and 7–30% for deletions. Although some of the indels have been previously reported in dbSNP, their population frequencies were only described in Caucasians for 5 of the 12 indels identified, and no frequencies were available in Mexican or Hispanic populations. All insertions were located in introns as were all but two of the deletions.

Insertions ranged from 1 to 4 base pairs in length and deletions ranged from 1 to 9 base pairs.

Linkage Disequilibrium Patterns in Salinas Mexicans

The linkage disequilibrium (LD) structure in 60 chromosomes of Salinas Mexican-Americans is shown graphically in Figure 2. The LD plot in this figure includes all SNPs (1,000 base pairs up and downstream of *PON1*) with MAF > 10% whose genotype distributions did not deviate significantly from Hardy–Weinberg equilibrium. Using the confidence interval definition of Gabriel et al. [2002], we found three haplotype blocks in the *PON1* gene for our cohort. Block 1 (5 kb) included the nonsynonymous SNP *PONI*₅₅ (rs854560). Haplotype block 2 (5 kb) included the main coding SNP *PONI*₁₉₂ (rs662) and haplotype block 3 spans the 3' UTR region. Overall, the LD plot demonstrates the existence of several smaller regions of strong LD separated by regions of high recombination rather than one large nonrecombinant block spanning the entire *PONI* gene region. The SNPs in the promoter region were also in high LD with each other although this small block did not meet the definitions of a haplotype block using the Gabriel et al. [2002] algorithm.

Functional Activity of *PONI* SNPs

Following resequencing of the *PON* cluster genes, we further genotyped 48 *PON* polymorphisms in 361 mothers and 339 children, 44 of which had MAFs > 0.05. Minor allele




Fig. 2. LD Plot of PON1 in Mexican-American mothers and children. This figure is a schematic of the LD structure of PON1 in a Mexican population from Salinas Valley, California. It includes SNPs with minor allele frequencies greater than 10% from introns, exons, and within regions 1,000 base pairs up and downstream of the PON1 gene. Only SNPs whose genotype distributions did not differ significantly from Hardy–Weinberg equilibrium were included ($n = 72$ SNPs). Known promoter SNPs *PON1*₋₁₀₈ and *PON1*₋₁₆₂, and coding SNPs *PON1*₅₅ and

*PON1*₁₉₂ are labeled in green. The numbers in the squares represent the correlation between SNPs (r^2). Squares are white if SNP pairs are not correlated ($r^2 = 0$), black if they are completely correlated ($r^2 = 1$), and gray if $0 < r^2 < 1$. Using the confidence intervals definition of haplotype blocks [Gabriel et al., 2002], we identified three haplotype blocks in PON1: one containing the *PON1*₅₅ SNP (Block 1), one containing the *PON1*₁₉₂ SNP (Block 2), and one near the 3' UTR region (Block 3).

frequencies are included in parentheses in Table I. Distributions of AREase and POase activities in newborns and mothers are shown graphically in Figure 3. In newborns, seven SNPs were associated with AREase activity after adjusting for multiple comparisons (Table III). The promoter SNP *PON1*₋₁₀₈, along with two SNPs in high LD with it (*PON1*₋₉₀₉ and rs854570), were strongly associated with AREase activity and the *PON1*₋₁₀₈ SNP had the most noticeable impact ($\beta = -8.8$ U/mL and $R^2 = 0.12$). The coding SNP *PON1*₅₅, along with three SNPs in high LD with it (rs854463, rs854561, and rs854549), was also associated with AREase activity ($\beta = -10.4$ U/mL and $R^2 = 0.10$).

In CHAMACOS mothers, there was a similar influence of promoter SNPs on AREase activity (Table III). However, the *PON1*₅₅ coding SNP and the two SNPs in high LD with it were no longer associated with AREase activity. Several variants not highly correlated to *PON1*₋₁₀₈ or *PON1*₁₉₂, including a deletion in the 5' UTR (FUTR_Del_ATG), one intronic SNP (rs3917328), one 3' UTR SNP (rs854550), one SNP located in the 3' UTR region of the nearby gene PPP1R9A (rs17773605), one *PON3* SNP, and two *PON2* SNPs were significantly associated with AREase activity.

SNPs rs3917328, rs854550, and rs17773605 are predicted microRNA (miRNA) binding sites [Xu and Taylor, 2009], suggesting a possible mechanism by which these SNPs could affect gene expression [Borel and Antonarakis, 2008].

In CHAMACOS newborns, the majority of SNPs with noticeable effect on AREase activity were also significantly associated with POase activity, which was anticipated since enzyme quantity also affects POase activity (Table III). The coding SNP *PON1*₁₉₂ was strongly associated with POase activity and explained 32% of POase variation. The single base pair deletion located in intron 7 (rs3917549) accounted for slightly more variance than *PON1*₁₉₂ (36%). This is likely due to its LD with both *PON1*₁₉₂ and *PON1*₋₁₀₈ SNPs. Four intronic SNPs (rs3917477, I1_SNP_A>C, rs62467349, rs2299255) not highly correlated ($R^2 < 0.20$) with the known functional PON1 SNPs (*PON1*₁₉₂, *PON1*₋₁₀₈, *PON1*₋₁₆₂, and *PON1*₅₅) were significantly associated with POase activity in newborns.

Similar to newborns, most of the SNPs associated with AREase activity also affected POase activity in CHAMACOS mothers. *PON1*₁₉₂ explained almost two-fold more POase variation in mothers (60%) compared




Fig. 3. Box plots of AREase and POase activities in newborns and mothers. (A) AREase activity (U/mL) was on average fourfold lower in newborns ($n = 203$) than mothers ($n = 250$). (B) POase activity (U/L) was also on average fourfold lower in newborns than mothers. Activity ranged from 7.42 to 742.8 U/L in newborns and from 75.2 to 3537.7 U/L in mothers.

to newborns (32%). In addition to the same four intronic SNPs that were associated with POase activity in newborns (rs3917477, I1_SNP_A > C, rs62467349, and rs2299255), two more intronic SNPs (I1_SNP_G > C, rs3917528), and two SNPs in the 3' UTR region (rs854551 and rs854550) were also associated with POase activity in mothers. As mentioned earlier, rs854550, which significantly affected AREase activity in mothers but not newborns, is a putative miRNA binding site [Xu and Taylor, 2009]. Using regression analysis, we found that including the intronic SNP rs3917550 into the model containing four known functional PON1 SNPs ($PON1_{-162}$, $PON1_{-108}$, $PON1_{55}$, and $PON1_{192}$), modestly (1.3%) but significantly improved assessment of functional significance of genetic variation on POase activity ($P = 0.02$, Wald test). Similarly, inclusion of either rs62467349, rs854550, or rs2299255 (all intronic SNPs) also yielded models that explained slightly more (0.2–0.7%) POase variance than the four functional SNPs alone ($P < 0.05$, Wald test).

Comparison of Phenotypic Effects of Single SNPs versus Their Haplotype Blocks

The majority of genetic studies involving PON1 primarily focus on known functional SNPs, particularly non-

synonymous coding SNPs $PON1_{55}$ and $PON1_{192}$. We sought to determine whether using these single SNPs in association studies with molecular phenotype adequately captures the variation of the entire haplotype blocks within which they reside. We performed regression modeling to calculate the variance of AREase and POase explained by single functional SNPs ($PON1_{55}$ and $PON1_{192}$) and inferred haplotypes comprising multiple SNPs within the same haplotype block (1 or 2). The results are presented in Table IV. In both newborns and mothers, inferred haplotypes containing the six SNPs in haplotype block 1 explained only 2–3% more of the variance of AREase activity than the $PON1_{55}$ SNP alone. In contrast, they explained threefold more POase variation (36–56%) than the $PON1_{55}$ SNP alone (11–16%). This threefold difference was likely driven by the strong correlation between two SNPs in this haplotype block (rs3917503 and rs854558) with $PON1_{192}$, a main determinant of POase activity.

In CHAMACOS newborns, the haplotype block 2 SNPs explained an additional 4% of POase variation compared to $PON1_{192}$ (32%) alone. In mothers, where the $PON1_{192}$ SNP explains almost twofold more POase activity variation (60%), the haplotype block 2 SNPs accounted for a similar amount of variation (62%).

TABLE III. Association of PON Polymorphisms with AREase and POase Activity in Newborns ($n = 203$) and Mothers ($n = 250$)

SNP	Position	Newborn AREase			Mother AREase			Newborn POase			Mother POase		
		Beta	R ²	P-value ^a	Beta	R ²	P-value ^a	Beta	R ²	P-value ^a	Beta	R ²	P-value ^a
FUTR_DeL_ATG ^b	94794927	4.0	0.02	0.16	15.5	0.04	0.02	26.3	0.01	0.20	-1.4	0.00	0.98
rs854572 ^c	94792632	-7.7	0.09	1.69 E-04	-19.6	0.09	4.69 E-05	-82.9	0.11	4.04 E-06	-387.1	0.17	2.51 E-11
rs705379	94791831	-8.8	0.12	1.62 E-05	-21.7	0.12	6.97 E-07	-88.3	0.14	2.19 E-07	-402.1	0.20	3.43 E-13
rs854570 ^{c,d}	94790628	7.0	0.07	7.85 E-04	11.9	0.03	0.03	88.3	0.13	6.74 E-07	241.5	0.06	1.20 E-04
II_SNP_G>C ^b	94790264	3.8	0.00	0.53	15.8	0.01	0.53	73.0	0.02	0.06	446.3	0.04	1.14 E-03
rs3917477	94789902	2.1	0.00	0.56	0.8	0.00	0.91	104.9	0.11	4.48 E-06	436.0	0.13	5.67 E-09
II_SNP_A>C ^b	94788215	2.8	0.00	0.57	9.9	0.01	0.31	101.8	0.05	1.87 E-03	469.5	0.08	1.64 E-05
rs2237583 ^c	94788113	0.6	0.00	0.87	-9.8	0.02	0.06	-36.6	0.02	0.04	-226.2	0.06	9.69 E-05
rs854569 ^c	94787991	1.9	0.00	0.53	4.4	0.00	0.43	74.3	0.08	6.85 E-05	303.2	0.10	4.85 E-07
rs2049649 ^e	94787265	-2.2	0.01	0.39	5.3	0.01	0.30	-31.9	0.02	0.05	-142.6	0.03	0.01
rs854566 ^d	94786685	1.0	0.00	0.87	7.2	0.00	0.45	-59.4	0.02	0.04	-327.7	0.04	1.31 E-03
rs854563 ^c	94785945	-10.5	0.10	5.60 E-05	-2.3	0.00	0.75	-101.0	0.10	7.59 E-06	-450.8	0.17	7.21 E-11
rs2074351 ^f	94785735	1.6	0.00	0.57	-0.5	0.00	0.91	56.5	0.05	2.57 E-03	416.9	0.18	1.31 E-11
rs854561 ^e	94784953	-10.5	0.10	5.60 E-05	-3.0	0.00	0.69	-102.3	0.11	6.34 E-06	-438.2	0.16	1.71 E-10
rs62467349	94784396	5.4	0.02	0.11	10.6	0.01	0.18	97.6	0.09	3.58 E-05	540.9	0.16	1.63 E-10
rs854560	94784020	-10.4	0.10	5.60 E-05	-2.9	0.00	0.69	-102.2	0.11	5.38 E-06	-453.2	0.16	1.63 E-10
rs3917503 ^{c,e,f}	94783389	-2.3	0.01	0.39	0.6	0.00	0.91	-121.5	0.28	7.18 E-15	-612.1	0.51	6.31 E-38
rs854558 ^f	94783310	4.0	0.02	0.11	3.9	0.00	0.55	-71.4	0.09	5.45 E-05	-482.9	0.22	3.25 E-14
rs3917506 ^f	94782120	0.8	0.00	0.84	-1.8	0.00	0.78	48.6	0.03	0.01	408.9	0.16	1.63 E-10
rs3917518 ^f	94779717	1.8	0.00	0.57	-2.3	0.00	0.75	110.7	0.14	1.56 E-07	479.9	0.18	1.28 E-11
rs3917521 ^f	94779351	0.2	0.00	0.96	-8.3	0.01	0.18	68.1	0.06	4.81 E-04	478.2	0.21	1.97 E-13
rs3917525 ^f	94778416	0.3	0.00	0.95	-8.1	0.01	0.18	69.7	0.07	3.84 E-04	473.1	0.21	1.63 E-13
rs3917528	94778176	-3.8	0.01	0.28	-20.8	0.05	2.60 E-03	3.3	0.00	0.93	166.1	0.02	0.05
rs2299255	94776722	5.5	0.03	0.10	10.0	0.01	0.18	108.0	0.10	1.22 E-05	565.8	0.18	1.28 E-11
rs2057681 ^f	94776193	1.4	0.00	0.57	-7.9	0.02	0.12	128.3	0.31	1.33 E-16	657.3	0.57	5.17 E-45
rs3917539 ^f	94775633	1.3	0.00	0.58	-8.9	0.02	0.08	126.1	0.29	2.84 E-15	640.4	0.55	1.12 E-42
rs3917541 ^f	94775560	2.3	0.01	0.53	-2.3	0.00	0.75	118.6	0.16	8.94 E-08	490.1	0.19	1.14 E-11
rs662	94775382	1.7	0.00	0.53	-4.9	0.01	0.53	131.8	0.32	1.73 E-17	682.9	0.60	3.70 E-49
rs3917542 ^f	94774628	0.2	0.00	0.96	-8.1	0.01	0.18	68.5	0.07	4.81 E-04	473.1	0.21	1.63 E-13
rs3917549 ^{c,f}	94773136	3.7	0.02	0.14	2.5	0.00	0.69	145.9	0.36	1.98 E-19	593.2	0.47	1.02 E-34
rs3917550	94772509	4.7	0.02	0.20	10.3	0.01	0.18	106.0	0.10	1.65 E-05	577.7	0.19	3.03 E-12
rs3917562 ^f	94770601	0.1	0.00	0.97	-13.9	0.05	4.20 E-03	77.5	0.11	5.38 E-06	379.4	0.18	1.22 E-11
rs854552 ^{c,f}	94765860	2.8	0.01	0.28	7.0	0.01	0.18	78.3	0.11	5.38 E-06	510.3	0.29	5.11 E-19
rs854551	94765613	3.2	0.01	0.43	14.5	0.02	0.11	18.5	0.00	0.50	320.1	0.05	1.14 E-03
rs854550	94765178	3.0	0.01	0.39	18.0	0.03	0.02	0.3	0.00	0.99	324.3	0.06	2.91 E-04
rs854549 ^e	94764521	-6.7	0.04	0.03	1.1	0.00	0.90	-75.3	0.06	1.24 E-03	-352.0	0.10	9.54 E-07
rs17773605	94762474	-2.1	0.00	0.57	-23.3	0.06	0.00	1.1	0.00	0.99	71.8	0.00	0.43
rs854547 ^f	94761792	0.5	0.00	0.87	-5.1	0.01	0.31	63.1	0.08	1.29 E-04	489.4	0.30	2.59 E-20
rs854544 ^f	94761327	-0.5	0.00	0.90	-4.4	0.00	0.40	53.3	0.05	2.31 E-03	457.7	0.28	1.27 E-18
rs13226149	94863536	3.1	0.01	0.28	17.3	0.05	4.20 E-03	23.0	0.01	0.26	77.0	0.00	0.31
rs2072200	94864096	0.1	0.00	0.97	-11.6	0.03	0.02	16.8	0.01	0.32	20.4	0.00	0.74
rs12026	94878952	3.2	0.01	0.28	16.3	0.04	0.01	11.4	0.00	0.61	86.1	0.01	0.25
rs7493	94872711	3.5	0.01	0.27	18.3	0.05	2.60 E-03	9.3	0.00	0.68	95.2	0.01	0.22

^aAdjusted for multiple comparisons using FDR method by Benjamini and Hochberg.^bUnknown insertions, deletions, and SNPs are named first for location (I, intron; E, exon; FUTR-5' UTR), type of polymorphism (Ins, insertion; Del, deletion, SNP), and then the base pair changes.^cLD (measured by r^2) > 0.2 with rs705379, *PONI*₋₁₀₈.^dLD (measured by r^2) > 0.2 with rs705381, *PONI*₋₁₆₂.^eLD (measured by r^2) > 0.2 with rs854560, *PONI*₅₅.^fLD (measured by r^2) > 0.2 with rs662, *PONI*₁₉₂.

TABLE IV. Proportion of Variance Explained for AREase and POase Activity by Single *PON1* tagSNPs and Their Haplotype Blocks

	Newborns (<i>n</i> = 203)		Mothers (<i>n</i> = 250)	
	AREase <i>R</i> ²	POase <i>R</i> ²	AREase <i>R</i> ²	POase <i>R</i> ²
rs854560, <i>PON1</i> ₅₅	0.10	0.11	<0.005	0.16
Haplotype Block 1 ^a	0.13	0.36	0.02	0.56
rs662, <i>PON1</i> ₁₉₂	<0.005	0.32	0.01	0.60
Haplotype Block 2 ^b	0.02	0.36	0.07	0.62

^aHaplotype Block 1 included the following SNPs: rs854563, rs2074351, rs854561, rs62467349, rs3917503, and rs854558.

^bHaplotype Block 2 included the following SNPs: rs3917541, rs3917542, rs3917549, and rs3917550.

DISCUSSION

In this study, we resequenced *PON* cluster genes *PON1*, *PON2*, and *PON3* in 16 children and 14 mothers of Mexican ancestry living in Salinas Valley, California, and identified more than 90 genetic variants, including indels, which have not been previously explored, and also some novel SNPs. Many of these variants had significantly different allele frequencies in comparison to Caucasians, despite an overall similar haplotype structure within the *PON* gene cluster. Several *PON* variants in CHAMACOS mothers and children, not in strong LD with main *PON1* SNPs ($R^2 < 0.20$), including a newly identified deletion in the 5' UTR, were found to be associated with AREase and POase activity that are predictive of susceptibility to OPs and oxidative stress. Multiple polymorphisms provided a modest improvement of the assessment of functional significance for *PON* levels and substrate-specific activities in comparison to the haplotype tagSNPs. Functional effects of *PON* genetic variation also differed by age and should be considered in protecting vulnerable subpopulations.

Overall, the distribution and location of haplotype blocks was similar in CHAMACOS Mexican-Americans from Salinas Valley, CA and Caucasians (HapMap data) with several regions of strong LD separated by regions of high recombination. In the CEPH population, Jarvik et al. [2003] described four nonrecombinant regions—one at the promoter region, one near the *PON1*₅₅ SNP, one encompassing the *PON1*₁₉₂ SNP, and one at the 3' UTR region. Likewise, in Salinas Mexicans, we observed high LD in the promoter region and identified haplotype blocks surrounding the two nonsynonymous coding SNPs (blocks 1 and 2) and the 3' UTR region (Block 3). While the LD structure in Salinas mothers and children appears similar to that found in Caucasians, we did observe one important difference between the two; in Mexicans, many SNPs in haplotype blocks 2 and 3 were highly correlated with each

other (across blocks), whereas these two blocks were more distinct with low LD between SNPs in CEPH subjects.

Although differences in LD structure between ethnic groups were modest, allele frequencies for some SNPs varied more noticeably. Several studies have previously demonstrated that the genotype distributions of the four main functional *PON1* SNPs (192, 55, -108, -162) vary widely across ethnic groups [Chen et al., 2003; Rojas-Garcia et al., 2005]. Here, we found allele frequencies of other *PON1* polymorphisms in our population were also quite different from other studied groups. For instance, 12 SNPs with MAF less than 5% in Caucasians had much higher frequencies (20% or higher) in Mexicans. These potentially important and common SNPs could easily be overlooked in other studies if they are rare in well-characterized populations. Our data may aid study design in future *PON* genetic association studies in Mexican and other Latino populations, providing more detailed data on LD structure and further informing tagSNP selection.

Indels are the second most frequent type of polymorphism in the genome and have been associated with human diseases [Zoghbi and Orr, 2000; Kondrashov and Rogozin, 2004; Sun et al., 2007]. Despite their potential relevance, few *PON1* indels have been functionally characterized. We observed four insertions and eight deletions in the *PON1* gene, four of which were novel. Furthermore, four deletions and one insertion were significantly associated with either AREase or POase activity. Since several of them were also correlated with the coding SNP *PON1*₅₅, it is not clear whether these associations are due to the indels themselves or to their LD with *PON1*₅₅. Future studies should include additional types of sequence variations like indels because they are common genetic variants with likely functional significance.

Genetic association studies often focus on coding SNPs, particularly nonsynonymous SNPs resulting in amino acid changes because they are likely to be functional. However, recent studies suggest that SNPs in other regions of the genome, including introns and 3'UTR regions may also have functional consequences. Intronic SNPs can affect splicing elements thereby influencing transcription and gene expression [Le Hir et al., 2003]. In our study, we identified several intronic SNPs which were associated with AREase and POase activity. Splicing is one potential mechanism explaining their impact on *PON1* phenotype. MicroRNA, which is involved in post translational regulation of gene expression, binds to sequences in the 3'UTR region [Borel and Antonarakis, 2008]. Several studies have shown SNPs in these miRNA binding sites can mediate regulation of gene expression [Abelson et al., 2005; Sethupathy et al., 2007]. In our study, we identified several SNPs in the 3'UTR that are predicted miRNA binding sites and were associated with AREase activity. Future studies employing reporter silencing assays may help to establish whether these

SNPs affect gene regulation through miRNA-mediated mechanisms.

Since the LD structure of *PON1* comprises 4 haplotype blocks in Caucasians, Jarvik et al. [2003] previously suggested that most of *PON1* variation could be captured using just the two promoter SNPs *PON1*₋₁₀₈ and *PON1*₋₁₆₂ and the two coding SNPs *PON1*₅₅ and *PON1*₁₉₂. Indeed many studies, including our own, have examined effects of these SNPs (and also *PON1*₋₉₀₉). In this study, we extended our analyses to include SNPs and indels spanning the entire *PON* gene cluster and identified several additional genetic variants associated with AREase and POase activity. However, in combination with the four known functional SNPs, they still only explain a small percentage of additional phenotypic variation. Particularly with AREase activity, other factors including genetic variants in other genes, environmental exposure or epigenetic modification may also influence *PON1* expression. We also found that similar to previous studies showing differences in the percent variation explained by the same SNPs in newborns and mothers [Chen et al., 2003; Holland et al., 2006], the relative contribution of some SNPs to *PON1* phenotype was different in these age groups. For instance, the 3' UTR SNP (rs854551) was not significantly associated to POase activity in newborns, yet was strongly associated with POase activity in mothers ($P = 1.14 \times 10^{-3}$). These data suggest that the role of specific genetic variants is not static and at different ages or physiological conditions (at the time of delivery), their relative influence on *PON1* phenotype may change.

In conclusion, we sequenced *PON* family genes in a cohort of Mexican-American children and mothers from Salinas Valley, CA, and identified several novel SNPs, and indels including several SNPs in introns and the 3'UTR, some of which were independently associated with *PON1* phenotype. Allele frequencies of many of the SNPs were quite different in our Mexican-American subjects in comparison to Caucasians. In addition, the relative genetic contribution of *PON1* SNPs toward molecular phenotype (enzyme activity) differed between mothers and their children. These functional effects of *PON* variation should be considered in protecting vulnerable subpopulations from OPs and other inducers of oxidative stress. Ethnic differences in the frequency and distribution of susceptible genotypes should also be taken into account in genetic association studies of *PON*.

ACKNOWLEDGMENTS

We gratefully acknowledge CHAMACOS staff, community partners, and especially the CHAMACOS participants. We appreciate the helpful discussions and comments from Drs. Asa Bradman and Kim Harley.

REFERENCES

- Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LS, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Sestan N, State MW. 2005. Sequence variants in *SLITRK1* are associated with Tourette's syndrome. *Science* 310:317–320.
- Aviram M, Rosenblat M. 2004. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. *Free Radic Biol Med* 37:1304–1316.
- Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD, haplotype maps. *Bioinformatics* 21:263–265.
- Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *J R Stat Soc Ser B (Methodological)* 57:289–300.
- Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. 2008. Relationship of paraoxonase 1 (*PON1*) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. *JAMA* 299:1265–1276.
- Borel C, Antonarakis SE. 2008. Functional genetic variation of human miRNAs and phenotypic consequences. *Mamm Genome* 19:503–509.
- Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (*PON1*) expression. *Am J Hum Genet* 68:1428–1436.
- Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on *PON1* activity in neonates. *Environ Health Perspect* 111:1403–1409.
- Chen J, Chan W, Wallenstein S, Berkowitz G, Wetmur JG. 2005. Haplotype-phenotype relationships of paraoxonase-1. *Cancer Epidemiol Biomarkers Prev* 14:731–734.
- Connelly PW, Maguire GF, Picardo CM, Teiber JF, Draganov D. 2008. Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. *J Lipid Res* 49:245–250.
- Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. 2003. Paraoxonase (*PON 1*) as a biomarker of susceptibility for organophosphate toxicity. *Biomarkers* 8:1–12.
- Costa LG, Cole TB, Vitalone A, Furlong CE. 2005a. Measurement of paraoxonase (*PON1*) status as a potential biomarker of susceptibility to organophosphate toxicity. *Clin Chim Acta* 352(1–2):37–47.
- Costa LG, Vitalone A, Cole TB, Furlong CE. 2005b. Modulation of paraoxonase (*PON1*) activity. *Biochem Pharmacol* 69:541–550.
- Deakin S, Leviev I, Brulhart-Meynet MC, James RW. 2003. Paraoxonase-1 promoter haplotypes and serum paraoxonase: A predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. *Biochem J* 372:643–649.
- Deakin SP, James RW. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. *Clin Sci (Lond)* 107:435–447.
- Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. 2005. Human paraoxonases (*PON1*, *PON2*, and *PON3*) are lactonases with overlapping and distinct substrate specificities. *J Lipid Res* 46:1239–1247.
- Erllich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, Farrer LA. 2006. Polymorphisms in the *PON* gene cluster are associated with Alzheimer disease. *Hum Mol Genet* 15:77–85.
- Eskenazi B, Bradman A, Gladstone E, Jaramillo S, Birch K, Holland N. 2003. CHAMACOS, a longitudinal birth cohort study: Lessons from the fields. *J Childrens Health* 1:3–27.
- Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, Eskenazi B. 2006. *PON1* status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenet Genomics* 16:183–190.

- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. 2002. The structure of haplotype blocks in the human genome. *Science* 296:2225–2229.
- Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Megeed R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. *Nat Struct Mol Biol* 11:412–419.
- Harley K, Eskenazi B, Block G. 2005. The association of time in the US, diet during pregnancy in low-income women of Mexican descent. *Paediatr Perinat Epidemiol* 19:125–134.
- Holland N, Furlong C, Bastaki M, Richter R, Bradman A, Huen K, Beckman K, Eskenazi B. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. *Environ Health Perspect* 114:985–991.
- Horke S, Witte I, Wilgenbus P, Kruger M, Strand D, Forstermann U. 2007. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. *Circulation* 115:2055–2064.
- Huen K, Richter R, Furlong C, Eskenazi B, Holland N. 2009. Validation of PON1 enzyme activity assays for longitudinal studies. *Clin Chim Acta* 402:67–74.
- Huen K, Harley K, Bradman A, Eskenazi B, Holland N. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. *Toxicol Appl Pharmacol* (in press).
- Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, et al. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. *Arterioscler Thromb Vasc Biol* 23:1465–1471.
- Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H. 2004. Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. *Ann Hum Genet* 68:110–119.
- Kondrashov AS, Rogozin IB. 2004. Context of deletions and insertions in human coding sequences. *Hum Mutat* 23:177–185.
- Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, Saito S, Miller NE, Hattori H. 2000. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. *J Lipid Res* 41:1358–1363.
- Landers JE, Shi L, Cho TJ, Glass JD, Shaw CE, Leigh PN, Diekstra F, Polak M, Rodriguez-Leyva I, Niemann S, Traynor BJ, McKenna-Yasek D, Sapp PC, Al-Chalabi A, Wills AM, Brown RH, Jr. 2008. A common haplotype within the PON1 promoter region is associated with sporadic ALS. *Amyotroph Lateral Scler* 9:306–314.
- Le Hir H, Nott A, Moore MJ. 2003. How introns influence and enhance eukaryotic gene expression. *Trends Biochem Sci* 28:215–220.
- Li HL, Liu DP, Liang CC. 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. *J Mol Med* 81:766–779.
- Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, Huang Y, Chen D, Xu X. 2005. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. *Genet Med* 7:58–63.
- Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. *Genomics* 33:498–507.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81:559–575.
- Rainwater DL, Rutherford S, Dyer TD, Rainwater ED, Cole SA, Vandenberg JL, Almasy L, Blangero J, Maccluer JW, Mahaney MC. 2009. Determinants of variation in human serum paraoxonase activity. *Heredity* 102:147–154.
- Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. 2005. Genetic polymorphisms and activity of PON1 in a Mexican population. *Toxicol Appl Pharmacol* 205:282–289.
- Sanghera DK, Manzi S, Minster RL, Shaw P, Kao A, Bontempo F, Kamboh MI. 2008. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. *Ann Hum Genet* 72:72–81.
- Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, Hatzigeorgiou AG, Antonarakis SE. 2007. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. *Am J Hum Genet* 81:405–413.
- Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D. 2007. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. *Nat Genet* 39:605–613.
- The International HapMap Consortium. 2003. The International HapMap Project. *Nature* 426:789–796.
- Xu Z, Taylor JA. 2009. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res* 37(Web Server issue):W600–W605.
- Zintzaras E, Hadjigeorgiou GM. 2004. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. *J Hum Genet* 49:474–481.
- Zoghbi HY, Orr HT. 2000. Glutamine repeats and neurodegeneration. *Annu Rev Neurosci* 23:217–247.